NCT06383052进行中（未招募）1 期
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Number of Patients With Dose Limiting Toxicity (DLT)
研究概览
简要总结
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years;
- •Histologically or cytologically confirmed adenocarcinoma of prostate；
- •Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3(PCWG3) criteria, which includes at least one of the following criteria: a.PSA progression;b.Objective radiographic progression in soft tissue; c.New bone lesions
- •Have serum testosterone < 50 ng/dL;
- •Patients with significant PSMA avidity on 68Ga-NYM032 PET/CT；
- •ECOG score of 0 or 1；
- •Expected life≥ 6 months;
- •Patients must have received at least one NAAD；
- •Patients must have received taxane-based chemotherapy or not be candidates for taxane chemotherapy；
- •Patients must have adequate organ and marrow function；
- •The subjects agree to take effective contraceptive measures during the study period and for at least three months after the drug administration:
- •The subjects are able to maintain good communication with the researchers, understand and follow the requirements of this study, voluntarily participate, and sign an informed consent form before the start of relevant research operations.
排除标准
- •Previous treatment with any of the following within 6 months before enrollment: Strontium-89,Samarium-153,Rhenium-186,Rhenium-188, Radium-223,hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed;
- •Any systemic anti-cancer therapy(e.g.chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 28 days prior to day of enrollment;
- •Site(s) of disease that are FDG positive with minimal PSMA expression ;
- •Any investigational agents within 28 days prior to day of enrollment;
- •Known hypersensitivity to the components of the 177Lu-NYM032 or its analogs;
- •Other concurrent investigational therapy;
- •Transfusion for the sole purpose of making a subject eligible for study inclusion;
- •Patients with a history of Central Nervous System (CNS) metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable,asymptomatic, and not receiving corticosteroids for the purposes of maintaining neurologic integrity, Patients with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired. For patients with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain (MRI preferred or CT with contrast);
- •A superscan as seen in the baseline bone scan;
- •Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression;
- •Concurrent serious (as determined by the Principal Investigator) medical conditions that in the opinion of the investigator would impair study participation or cooperation;
- •Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are patients with adequately treated non-melanoma skin cancer, superficial bladder cancer;
- •Eligible for treatment(s) other than ARDT based on the presence of any mutations or biomarkers that are known as predictors of better response (e.g., AR-V7 or BRCA).
研究组 & 干预措施
177Lu-NYM032 injection
Experimental
干预措施: 177Lu-NYM032 injection (Drug)
结局指标
主要结局
Number of Patients With Dose Limiting Toxicity (DLT)
时间窗: 28 days
Dose limiting toxicity is determined by monitoring for adverse events following therapy.
Maximum Tolerated Dose (MTD)
时间窗: 28 days
Maximum tolerated dose (MTD) is determined by monitoring dose-limiting toxicity and adverse events in the dosing cohorts
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsProstatic DiseaseProstate CancerProstatic NeoplasmsNCT05150236Australian and New Zealand Urogenital and Prostate Cancer Trials Group93
进行中（未招募）
2 期
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate CancerProstate CancerNCT00859781Weill Medical College of Cornell University55
进行中（未招募）
3 期
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentMetastatic Castration-Resistant Prostate CancerNCT04647526POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company455
招募中
2 期
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsMetastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8NCT05691465National Cancer Institute (NCI)35
已完成
2 期
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer PatientsSalivary Gland CancerSalivary Duct CarcinomaAdenoid Cystic CarcinomaNCT04291300Radboud University Medical Center12